Terraform Industries' Casey Handmer on why solar beats nuclear, what happened in 1971, and rage-quitting NASA

Summary

Casey Handmer quit NASA JPL three and a half years ago to found Terraform Industries, which makes synthetic natural gas from sunlight and air. The conversation ranges from DOGE and stagnation to why solar wins over nuclear — and why deep tech founders who ignore economics tend to fail.

Solar vs. nuclear

Handmer's case against nuclear isn't ideological. He argues that reactors are fundamentally steam engines running on the Rankine cycle, which carries irreducible costs in turbines and steam infrastructure that keep the economics worse than coal — even if you could buy enriched uranium on Amazon tomorrow. Solar sidesteps all of that. Factories worldwide are now producing more than a terawatt of solar annually, with output growing 30–40% per year, and the positive feedback loop is already running. No moving parts, no special labor to install, commoditized at scale.

His land-use framing is striking: powering every person on Earth to US consumption levels — roughly 20 barrels of oil equivalent per person per year — would require covering about 6% of Earth's surface in solar panels. That's less than current agricultural land use for grazing, row crops, and forestry combined.

On Chinese solar panels and tariffs, Handmer is blunt: if a geopolitical adversary is subsidizing panels at their own taxpayers' expense, the rational response is to buy as much as possible, not restrict imports.

What happened in 1971

Handmer treats the post-1971 productivity slowdown as overdetermined — Henry Kaiser died in 1967, OPEC oil shocks followed, NEPA and CERCLA passed in the early 1970s — but argues the real test is simple: either total factor productivity grows or it doesn't, and everything else is noise. Without Moore's Law, he thinks the stagnation would have been far worse. His optimism rests on solar, AI, and what he reads as a new willingness to at least measure and discuss the problem.

NASA and DOGE

Handmer's experience at NASA JPL was that brilliant people spent most of their time being actively blocked from doing extraordinary work, and punished for going above and beyond. He contrasts this with China's space program, where program managers fear the consequences of failure. NASA's don't. He hopes DOGE directs attention there, though he doesn't predict it will.

On Musk more broadly, Handmer argues the conventional read a year ago — that political involvement would backfire — missed the risk Musk actually took and underestimated what he was doing. He frames DOGE's critics as suffering from an "outside context problem" (a concept from Iain M. Banks's Culture novels): the outrage is real but disconnected from what's actually happening, which makes the criticism unconstructive.

Hard tech investing

Handmer's advice to VCs eyeing deep tech is to look at history rather than theory. The most reliable pattern for scaling major innovations isn't a VC-backed startup from scratch — it's an existing organization with capital relationships, large skilled teams, and aggressive execution taking on a new class of problem. He cites the Elon industrial complex and Henry Kaiser (who built 1,500 ships in World War II and stood up a shipyard in under two months in 1941) as examples.

The sharper point is on economics: deep tech founders who build something technically real but commercially nonviable are the nightmare scenario. Handmer mentions nuclear companies that had a single wrong number in their spreadsheet model and built the thing — only to find it uncompetitive on the grid. His rule is that you cannot fight capitalism at massive scale; you have to have it working with you, not against you.

The longevity argument

Handmer closes on what actually scares him: that when life-extension drugs are eventually developed, we'll discover they could have been built since the 1930s, meaning billions of people died unnecessarily. He ties it to fiscal policy — 1% of the federal budget goes to dialysis alone, and the US spends less than 0.1% of the national health budget on anti-aging research. A 10% increase in human lifespan, he argues, would cut entitlement spending by roughly 10% just from mortality reduction.